Plasma hPG80 circulating prograstin levels in cancer patients in Nigeria: Prolevcan study.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 3029-3029
Author(s):  
Omolara A. Fatiregun ◽  
Dominique Joubert ◽  
Berengere Vire ◽  
Abigail Anni Frances Simon-Hart ◽  
Olaniyi Andrew Adekeye ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Healthy Volunteers ◽  
Cancer Patients ◽  
Cancer Detection ◽  
Blood Test ◽  
Blood Levels ◽  
Breast Cancers ◽  
Potential Utility ◽  
Treatment Assessment ◽  
Colorectal Cancer Patients

3029 Background: Progastrin is a tumor-promoting peptide which is detectable in the blood of patients with different cancers. hPG80 (circulating progastrin) is produced by cancer cells. Recently it was reported that hPG80 is detected in the blood of cancer patients, suggesting its potential utility for cancer detection. In this Nigerian study, we assessed the performance of hPG80 in diagnosed cancer patients versus healthy volunteers. Methods: Plasma samples of 50 patients with breast (n = 41) and colorectal (n = 9) cancer, aged from 26 to 70 years, were assayed for hPG80 levels with the DxPG80 kit from ECS-Progastrin. The diagnostic performance (ROC AUC) of hPG80 was assessed compared to 50 healthy volunteers aged from 21 to 38 years. Results: Plasma hPG80 levels were significantly higher in cancer patients compared to controls (median values: 4.59 pM (IQR: 2.02-8.27 pM) vs 1.37 pM (IQR: 0-3.11 pM), p < 0.0001). The median value of hPG80level was 3.96 pM (IQR: 1.61-7.89 pM) for breast cancers and 6.43 pM (IQR: 2.80-15.86 pM) for colorectal cancer patients. ROC AUC for all cancers, breast cancer and colorectal cancer were 0.75, 0.74 and 0.82 respectively. There was no correlation between hPG80 blood levels with age or CA15.3 levels. Conclusions: Plasma hPG80 is a simple and relatively affordable blood test, it shows potential utility as a biomarker for cancer detection, monitoring and treatment assessment. Further prospective studies are needed to explore and confirm its potential.

The correlation of thrombin-activated fibrinolysis inhibitor (TAFI) levels and clinicopathologic factors in advanced colorectal cancer patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e22217-e22217
Author(s):  
T. Salman ◽  
A. Bilici ◽  
B. O. Ustaalioglu ◽  
M. Seker ◽  
B. Sonmez ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factors ◽  
Cancer Patients ◽  
Large Scale ◽  
Performance Status ◽  
Blood Levels ◽  
Thromboembolic Events ◽  
Fibrinolysis Inhibitor ◽  
Clinicopathologic Factors ◽  
Colorectal Cancer Patients

e22217 Background: There are many ongoing researchs for novel prognostic factors in colorectal cancers. Increased thromboembolic events were associated with poor prognosis and survival in cancer patients. Thrombin-activated fibrinolysis inhibitor (TAFI), which has inhibitory effects on fibrinolysis, was proven to play a major role in hypercoagulopathy and was reported to reach high blood levels in cancer patients compared to those in the general population. Methods: TAFI levels were measured. The correlation between those levels and clinicopathologic features were analyzed in 82 patients with advanced stage colorectal cancer receiving treatment in our clinic. Results: Eighty-two patients were evaluated. Patients characteristics included 54 males (65.9%), 28 females (34.1%); median age 56.4 (range:24–76). The mean TAFI levels was 198,36±70,01 Ğer yazali and TAFI levels were found to be high in 70% of patients. High levels of TAFI were more common in rectum cancer patients compared with colon cancer patients. There was no significant correlation between TAFI levels and clinicopathologic factors, such as age, sex, body mass index, performance status, number of metastases, grade, vascular invasion, perineural invasion and CEA levels. The TAFI levels of patients receiving bevacizumab (202.1±66.6) were more higher than those no receiving (191,83±76,21), but this association was not statistically significant (p>0.05). Conclusions: Although the statistical analysis proved insignificant in our study, the effect of thromboembolic events on prognosis and survival is well established. Thus, large scale prospective studies are required to determine prognostic factors. No significant financial relationships to disclose.

scholarly journals Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers

2011 ◽  
Vol 6 (2) ◽  
pp. 320-329 ◽  
Author(s):  
Tingting Wang ◽  
Guoxiang Cai ◽  
Yunping Qiu ◽  
Na Fei ◽  
Menghui Zhang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Gut Microbiota ◽  
Healthy Volunteers ◽  
Cancer Patients ◽  
Colorectal Cancer Patients

scholarly journals Elevated plasma phospholipase A2and platelet-activating factor acetylhydrolase activity in colorectal cancer

2004 ◽  
Vol 13 (1) ◽  
pp. 53-54 ◽  
Author(s):  
Yves Denizot ◽  
Véronique Truffinet ◽  
Stéphane Bouvier ◽  
Alain Gainant ◽  
Pierre Cubertafond ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Study ◽  
Cancer Patients ◽  
Inflammatory Mediator ◽  
Platelet Activating Factor ◽  
Blood Levels ◽  
Elevated Plasma ◽  
Platelet Activating Factor Acetylhydrolase ◽  
Colorectal Cancer Patients ◽  
Clinical Study Reports

This clinical study reports that blood levels of the pro-inflammatory mediator platelet-activating factor (PAF) did not change in colorectal cancer patients. In contrast, plasma levels of two enzymatic activities, one implicated in PAF production (i.e. phospholipase A2) and one in PAF degradation (i.e. PAF acetylhydrolase activity) were significantly elevated.

scholarly journals Diagnostic Yield of the Immunochemical Fecal Occult Blood Test in Asymptomatic First Degree Relatives of Colorectal Cancer Patients

2011 ◽  
Vol 140 (5) ◽  
pp. S-406 ◽  
Author(s):  
Antonio Z. Gimeno-García ◽  
Marta Carrillo-Palau ◽  
Manuel Hernández-Guerra ◽  
David Nicolás-Pérez ◽  
Inmaculada Alonso-Abreu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Blood Test ◽  
Fecal Occult Blood Test ◽  
Diagnostic Yield ◽  
Occult Blood ◽  
Fecal Occult Blood ◽  
Occult Blood Test ◽  
Fecal Occult ◽  
Colorectal Cancer Patients

Changes of reduced glutathione and glutathione S-transferase levels in colorectal cancer patients undergoing treatment

2018 ◽  
Vol 104 (5) ◽  
pp. 375-380
Author(s):  
Edita Baltruskeviciene ◽  
Birutė Kazbariene ◽  
Eduardas Aleknavicius ◽  
Aurelija Krikstaponiene ◽  
Lina Venceviciene ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Healthy Volunteers ◽  
Cancer Patients ◽  
Treatment Process ◽  
Reduced Glutathione ◽  
Response To Treatment ◽  
Enzyme Linked Immunosorbent Assay ◽  
Glutathione S Transferase ◽  
Treatment Type ◽  
Colorectal Cancer Patients

Purpose: The available data concerning reduced glutathione (GSH) and glutathione S-transferase (GST) levels in colorectal cancer patients during the treatment process are contradictory and insufficient. Methods: Forty patients with metastatic colorectal cancer receiving FOLFOX4 chemotherapy with or without bevacizumab and 40 healthy volunteers were included in the study. Blood samples were taken before treatment, after 2 months and at the end of treatment in the patient group and once in the healthy volunteer group. The levels of GSH and GST in blood serum were evaluated by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s instructions. Results: The serum level of GSH was significantly lower in colorectal cancer patients before treatment than in healthy volunteers (37.84 ± 19.39 μg/mL and 52.78 ± 19.39 μg/mL, respectively; p<0.001). After treatment, the level of GSH increased significantly, while the level of GST decreased significantly. These changes were observed only in the groups of patients with partial or complete response, having metastases only in the liver, receiving FOLFOX4 chemotherapy with bevacizumab, or undergoing resection or radiofrequency ablation of liver metastases. Conclusions: GSH and GST levels change significantly during the treatment process and these changes depend on the response to treatment, treatment type, and site of metastases. Further analysis of the changes in GSH and GST levels during treatment would allow the assessment of the predictive potential of this molecular marker.

scholarly journals DNA integrity index as a potential molecular biomarker in colorectal cancer

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Ramy Salem ◽  
Rasha Ahmed ◽  
Karim Shaheen ◽  
Mohammed Abdalmegeed ◽  
Heba Hassan
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Cancer Detection ◽  
Diagnostic Sensitivity ◽  
Dna Integrity ◽  
Integrity Index ◽  
Potential Biomarker ◽  
Healthy Control ◽  
Colorectal Cancer Patients ◽  
Better Than

Abstract Background Efficient approaches for early detection of colorectal cancer offer opportunities to gain better treatment outcomes. Blood-based molecular biomarkers as DNA integrity index (DII) might represent a promising tumor marker in the future. The purpose of this study was to assess the clinical utility of the DII as a potential biomarker for colorectal cancer in 90 colorectal cancer patients, 30 patients with benign colorectal mass, and 30 age- and sex-matched healthy control subjects. PCR was used to assess the concentration of both ALU115 and ALU247. DII was calculated as the ratio of Q247/Q115. Results DII was significantly higher in colorectal cancer patients than both patients with benign colorectal mass and healthy controls. ROC curve was plotted using DII and the best cut-off was ≥ 0.60 with diagnostic sensitivity 93.0%, specificity 65.0%, PPV 80.0%, NPV 86.0%, and efficiency 82% with AUC (0.872) while the best cut-off for CEA was ≥ 1.4 ng/mL with diagnostic sensitivity 87.0%, specificity 60.0%, PPV 76%, NPV 75%, and efficiency 76% with AUC (0.79). Conclusions Our results suggest that DII is better than CEA as an early marker for colorectal cancer detection and may be used as a candidate biomarker for malignancy.

Associations of daily partner responses with fatigue interference and relationship satisfaction in colorectal cancer patients.

2018 ◽  
Vol 37 (11) ◽  
pp. 1015-1024
Author(s):  
Fabiola Müller ◽  
Marrit A. Tuinman ◽  
Ellen Stephenson ◽  
Ans Smink ◽  
Anita DeLongis ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Relationship Satisfaction ◽  
Cancer Patients ◽  
Colorectal Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document